Physician profile
Amy E Brose
NPI 1215964366
$4,463.91
in general payments reported to CMS, 2019-2025
33 companies · $193 in 2025
The $193 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $516 · 2020: $514 · 2021: $1,025 · 2022: $1,287 · 2023: $570 · 2024: $360 · 2025: $193.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,223.14 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $538.37 | 2019-2023 | Evusheld, Farxiga, Breztri |
| Pfizer INC. | $452.45 | 2019-2025 | |
| Amgen INC. | $285.14 | 2019-2025 | Otezla, Repatha, Otezla |
| Novo Nordisk INC | $270.79 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $243.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $218.66 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $160.50 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $143.66 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $107.71 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $95.00 | 2020-2022 | |
| Allergan, INC. | $83.97 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $80.14 | 2022 | |
| Amarin Pharma, INC. | $69.94 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $62.05 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $61.00 | 2022 | |
| Abbott Laboratories | $41.50 | 2021-2023 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $40.37 | 2021 | |
| Neurelis, INC. | $32.96 | 2023 | Valtoco |
| Nestle Healthcare Nutrition INC. | $27.43 | 2021 | |
| Currax Pharmaceuticals LLC | $25.24 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $23.98 | 2021 | |
| Organon LLC | $23.61 | 2025 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $22.60 | 2022 | |
| Astellas Pharma US INC | $18.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $18.02 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.18 | 2021 | |
| Alnylam Pharmaceuticals INC. | $14.95 | 2023 | Amvuttra |
| Kowa Pharmaceuticals America, INC. | $13.60 | 2020 | |
| Eisai INC. | $13.48 | 2021 | |
| Sanofi Pasteur INC. | $12.08 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.83 | 2020 | |
| Esperion Therapeutics, INC. | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Brose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.